Nonalcoholic fatty liver disease (NAFLD) is due to the excessive lipid accumulation within hepatocytes. Metabolic nuclear receptors (MNRs) play great roles in lipid homeostasis. We have identified a novel long noncoding RNA (lncRNA), lnc-HC, which regulates hepatocytic cholesterol metabolism through reducing Cyp7a1 and Abca1 expression. Here, we further elucidate its roles in hepatic fatty acid and triglyceride (TG) metabolism through a novel lncRNA regulatory mechanism. The most prominent target of lnc-HC identified by in vitro study is PPARg. Further studies revealed that lnc-HC negatively regulates PPARg at both the mRNA and protein levels and suppresses hepatocytic lipid droplet formation. Importantly, the function of lnc-HC in regulating PPARg expression depends on modulating miR-130b-3p expression from the transcriptional to the post-transcriptional level, not through lncRNA's critical modulating patterns. In vivo, the reduction of lnc-HC expression significantly decreases miR-130b-3p expression, induces PPARg expression, and increases TG concentration in rat livers with hyperlipidemia. These findings further help in understanding the regulatory pattern of lnc-HC in hepatic lipid metabolism and might present a possible therapeutic target for improving lipid homeostasis.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is one type of fatty liver disease that occurs in liver as lipid accumulation and hepatic steatosis due to causes other than alcohol uptake. NAFLD ranges from nonalcoholic fatty liver to nonalcoholic steatohepatitis, hepatic fibrosis, and cirrhosis, 1,2 and can even become hepatic carcinoma. 3, 4 Furthermore, NAFLD is also closely associated with type II diabetes, atherosclerosis, and cardiovascular disease. [4] [5] [6] Recent studies indicate that over 30% of people in the United States and up to 25% of adults worldwide have NAFLD. 7, 8 Although a growing number of studies help us understand the pathogenesis of NAFLD, we still lack an approved therapeutic regime due to its complexity. Thus, exploring the pathological process of NAFLD and discovering the critical drug targets could greatly contribute to understanding the molecular mechanism and supplying promising therapeutic candidates.
NAFLD manifests hepatocellular lipid deposits and injury as the main pathological change, which is caused by lipid disorder. Metabolic nuclear receptors (MNRs), as a big class of transcription factors (TFs), are critical contributors to energy and lipid homeostasis. MNR family contains peroxisome-proliferator-activated receptors (PPARs), liver X-activated receptors (LXRs), and the farnesoid X receptor (FXR). 9, 10 PPARs mainly participate in lipogenesis and insulin resistance. PPARg powerfully regulates fatty acid uptake and storage and has been implicated in the pathology of obesity, diabetes, and atherosclerosis. 11, 12 Although PPARg is a well-known therapeutic target in the treatment of hyperlipidemia and hyperglycemia in type 2 diabetes, PPARg agonist causes adverse events such as liver function disorder and weight gain. 13 Existing studies have identified important roles for long noncoding RNAs (lncRNAs) in lipid metabolism. [14] [15] [16] [17] Ectopic expression of the lncRNA HOTAIR in abdominal preadipocytes could upregulate adipogenic gene expression of PPARg and lipoprotein lipase (LPL) and induce the adipocyte differentiation. 18 Blnc1 interacts with transcription factor EBF2 and promotes brown and beige adipocyte differentiation, which is linked to thermogenesis and systemic energy homeostasis. 19 The lncRNA lncLSTR regulates lipid homeostasis through TDP-43/FXR/apoC2 molecular pathways. 20 In our previous study, we identified a novel lncRNA, lnc-HC (a lncRNA derived from hepatocytes), differentially expressed in NAFLD rat livers. lnc-HC directly binds the co-regulator hnRNPA2B1 and further interacts with cholesterol catabolic gene Cyp7a1 or Abca1 as a lncRNA-protein-mRNA complex. lnc-HC regulates Cyp7a1 and Abca1 expression through hnRNPA2B1 and, thus, modulates hepatic cholesterol catabolism. 21 Based on our previous work, we further identified the function of lnc-HC in controlling hepatic fatty acid and triglyceride (TG) metabolism. Our present work suggests that lnc-HC negatively regulates PPARg expression at the post-transcriptional level through the mediator miR-130b-3p; the lnc-HC/miR-130b-3p/PPARg pathway delicately regulates the accumulation of hepatic lipid droplet.
RESULTS

lnc-HC Participates in Hepatocytic Fatty Acid Metabolism
We first induced the lipid accumulation cell model by treating CBRH-7919 and BRL3A cells with mixed free fatty acids (FFAs; 1 mM; palmitic acid [PA], oleic acid [OA]; PA:OA, 1:2) for 24 h. Oil red O staining showed obvious formation of lipid droplets in CBRH-7919 cells (Figure 1A) . Meanwhile, quantitative real-time PCR results showed the expression change of the lipid metabolic enzymes fatty acid synthase (Fasn; 80% decrease), carnitine palmitoyl transferase 1A (Cpt-1a; over 7-fold increase), and diacylglycerol O-acyltransferase 2 (Dgat2; 1.65-fold increase) and the expression change of the lipid MNRs PPARa (25% decrease), PPARg (1.8-fold increase), FXR (2.1-fold increase), and Srebp1c (70% decrease) in the lipid accumulation cell model (Figures 1B and 1C) . We observed a time-course-dependent increase of lnc-HC with FFA treatment, while its overlapping gene Slc25a15 remained unchanged ( Figure 1D ). Within the FFA-treated BRL3A cells, we observed the similar results as lipid droplet accumulation ( Figure S1A ), FFA metabolism-associated gene changes (Figures S1B and S1C), and lnc-HC upregulation ( Figure S1D ). This phenomenon suggests that lnc-HC takes part in hepatic FFA and TG metabolism. 
lnc-HC Negatively Regulates MNR PPARg
To figure out whether lnc-HC interacts with MNRs and its potential role in hepatocytic FFAs and TG metabolism, we analyzed the expression of MNRs in lnc-HC overexpressed and stable-knockdown cell lines, respectively named overLnc-HC CBRH and Lnc-HCshR CBRH. In overLnc-HC CBRH cells, mRNA expression of PPARg and LXRa was significantly decreased (Figure 2A ). In Lnc-HCshR CBRH cells, only PPARg mRNA was increased (Figure 2B) . Western blotting analysis showed consistent results that lnc-HC could negatively regulate PPARg protein expression (Figure 2C) . Also, lnc-HC negatively regulated PPARg expression both at the mRNA and the protein levels in BRL3A cells (Figures S2A and S2B). PPARg comprehensively controls the TG synthesis and storage process. Here, quantitative real-time PCR analysis showed that TG-synthesis-associated genes, including Acc2, Acsl1, and Dgat2, were negatively regulated by lnc-HC and that their expressions were consistent with PPARg variation ( Figure 2D ). In addition, lnc-HC negatively regulated FFA uptake genes Fatp-1 and aP2 and the FFA b-oxidation gene Cpt-1a ( Figure 2D ). With the transfection of PPARg small interfering RNA (siPPARg; GenePharma, Shanghai, China) in Lnc-HCshR CBRH cells, PPARg expression was knocked down at the mRNA and protein levels ( Figures 2E and 2F) ; meanwhile, the expression of PPARg downstream genes, including aP2, Acc2, Dgat2, and Fatp-1, which were originally increased with lnc-HC knockdown, was decreased as compared with the negative control (NC) small interfering RNA group (siNC; GenePharma, Shanghai, China) ( Figure 2G ). Here, we confirmed that lnc-HC negatively regulated the expression of PPARg and its pathway genes.
lnc-HC Controls miR-130b-3p Expression
The half-life of PPARg mRNA was measured in lnc-HC interfered stable cell lines by the treatment of a-amanitin over 24 h to block RNA transcription by RNA polymerase II, using 18S rRNA as the normalizer control. Overexpression of lnc-HC reduced the halflife of the PPARg transcript, while lnc-HC knockdown prolonged the half-life of the PPARg transcript ( Figure 3A ). These results showed that lnc-HC negatively regulated PPARg expression at the post-transcriptional level. As previously reported, lnc-HC regulates cholesterol catabolic genes Cyp7a1 and Abca1 through direct interaction with hnRNPA2B1 protein. In this study, RNA immunoprecipitation (RIP) with hnRNPA2B1 protein showed that hnRNPA2B1 could not bind the PPARg transcript ( Figure 3B ). An RNA pulldown assay also doubly confirmed that, after the combination of lnc-HC and nucleoprotein (NP), there was no PPARg transcript binding with the lnc-HC-NP complex ( Figure 3C ). In the RNA pulldown and hnRNPA2B1 RIP assay, Cyp7a1 was used as positive control, which has been verified to directly interact with hnRNPA2B1. To validate the direct interaction between lnc-HC and the PPARg transcript, we performed a GFP-RIP assay following quantitative real-time PCR. The result indicates that lnc-HC could not enrich the PPARg transcript, using immunoglobulin G (IgG) as NC and input as loading control ( Figure 3D ).
As we know, microRNAs (miRNAs) modulate gene expression at the post-transcriptional level. We used miRanda and TargetScan software to predict miRNA candidates regulating PPARg expression, and predicted miRNAs include miR-130a-3p, miR-130b-3p, miR-301a-3p, and miR-301b-3p ( Figure 3E ). To confirm whether lnc-HC controls expression of these candidates, we conducted quantitative real-time PCR in lnc-HC-interfered CBRH-7919 and BRL3A cell lines. Results displayed that only miR-130b-3p expression was significantly increased with lnc-HC overexpression and decreased with lnc-HC knockdown ( Figures 3F and S3A ). Further, we checked the expression of primary (pri-), precursor (pre-), and mature miR-130b-3p in lnc-HC knockdown and NC control cell lines. With lnc-HC knockdown, pri-miR-130b was decreased (23% decrease), pre-miR-130b was expressed to a lower level (50% decrease), and miR-130b-3p was 42% decreased ( Figure 3G ), which suggests that miR-130b-3p is regulated www.moleculartherapy.org by lnc-HC from the transcriptional level to the post-transcriptional level. Subsequently, we constructed a reporter gene vector of the miR-130b-3p promoter region as the pGL3-130b-3p-promoter and conducted a dual-luciferase reporter assay. Results showed that miR-130b-3p promoter activity increased with lnc-HC overexpression and decreased with lnc-HC knockdown ( Figures 3H and S3B ). As previously described, the second structure of lnc-HC contains a 5 0 stemloop, a central stem-loop, and a 3 0 stem-loop. 21 Here, a dual-luciferase reporter gene assay confirmed that the 5 0 stem-loop (1-480 bp) of lnc-HC is critical for controlling miR-130b-3p promoter activity (Figures 3I and S3C) .
miR-130b-3p
Modulates PPARg Expression miR-130b-3p mimics and inhibitor (GenePharma, Shanghai, China) were used to check the regulation between miR-130b-3p and PPARg expression. Mimics significantly reduced the PPARg mRNA level in CBRH-7919 cells, which was originally upregulated by lnc-HC knockdown ( Figure 4A ). Consistent with the mRNA change, miR-130b-3p mimics also decreased PPARg protein expression ( Figure 4B ). On the contrary, PPARg was increased in CBRH-7919 cells after the treatment of miR-130b-3p inhibitor, at both the mRNA and protein levels ( Figures 4C and 4D) . Similarly, miR-130b-3p mimics strongly suppressed PPARg expression, and miR-130b-3p inhibitor stabilized PPARg expression in BRL3A cells ( Figures S4A and S4B ). We further constructed the reporter gene vectors pPPARg-3 0 UTR-wild and pPPARg-3 0 UTR-mut ( Figure 4E ). After transient co-transfection of CBRH-7919 cells with miR-130b-3p mimics/mNC (NC mimic) or miR-130b-3p inhibitor/iNC (NC inhibitor) and reporter gene vector pPPARg-3 0 UTR-wild/mut, cells were collected to perform a dualluciferase reporter gene assay. In the pPPARg-3 0 UTR-wild transfection group, the relative luciferase activity was decreased with miR-130b-3p mimic treatment, while it was increased with inhibitor treatment. In addition, these changes were faded in the pPPARg-3 0 UTR-mut transfection group ( Figure 4F ). Thus, we demonstrated that miR-130b-3p decreases PPARg expression through binding the PPARg 3 0 UTR. Combined with evidence that lnc-HC positively regulates miR-130b-3p expression, it is indicated that lnc-HC controls PPARg expression through the post-transcriptional modulator miR-130b-3p. and 5B). Consistently, the concentration of intracellular FFAs and TGs was further increased in Lnc-HCshR CBRH cells as compared with NCshR CBRH cells ( Figures 5C and 5D ). It seems contradictory that lnc-HC expression was upregulated in hepatocytes with FFA treatment, but lnc-HC knockdown increased lipid accumulation. Thus, we analyzed lnc-HC and PPARg expression in lnc-HC stably interfered cells with vehicle and FFA treatment. Quantitative realtime PCR results showed that PPARg was upregulated with FFA treatment, while its increase was much higher with the decrease of lnc-HC in lnc-HCshR CBRH-7919 cells; and miR-130b-3p expression was consistent with lnc-HC ( Figure 5E ). These results suggest that excessive FFA treatment increases lnc-HC and PPARg expression; without lnc-HC upregulation, PPARg could increase to a higher level and lead to excessive accumulation of lipid droplets in hepatocytes.
Next, we verified the effect of the lnc-HC/miR-130b-3p/PPARg pathway on hepatocytic lipid accumulation. We respectively transfected overLnc-HC CBRH cells with miR-130b-3p inhibitor and transfected Lnc-HCshR CBRH cells with miR-130b-3p mimics for 24 h and then treated cells with FFAs for 12 h. Oil red O staining showed that lipid droplet content was reduced with lnc-HC overexpression, while it increased with the transfection of miR-130b-3p inhibitor in overLnc-HC CBRH cells ( Figures 5F and 5G ). On the contrary, hepatocytic lipid accumulation was clearly increased with lnc-HC knockdown, while it decreased with the treatment of miR-130b-3p mimics in the lnc-HCshR CBRH cell line ( Figures 5H and 5I ). These results strongly indicated that the lnc-HC/miR-130b-3p pathway suppresses hepatocytic lipid accumulation in vitro.
The Suppression of lnc-HC Aggravates Hepatic Lipid Disorder
Next, we checked the in vivo effect of lnc-HC in hepatic lipid metabolism. Previously, E3 rats were treated with a high-fat, high-cholesterol diet (HCD; 10% fat, 4% cholesterol and 2% sodium cholate) for 8 weeks to induce a hepatic lipid disorder condition. 21 H&E staining results showed that there was no macroscopic lipid droplet accumulation in the livers of the HCD and the HCD-plus-NCshR groups, but visible hepatic steatosis was already developed in the HCD-plus-lnc-HCshR group ( Figure 6A ). Serum lipid profiles were changed, TG and low-density lipoprotein-cholesterol (LDL-C) were significantly increased in the HCD group, and high-density lipoprotein-cholesterol (HDL-C) was decreased in the HCD group as compared with the control group; lnc-HC knockdown by using shRNA could improve serum parameters such as TG and HDL-C, but no effect was evident on serum LDL-C ( Figure 6B ). In addition, compared with the control group, the other three groups all showed higher liver/body weight ratios and significant increase of body weight gain ( Figures 6C and 6D) . Here, we focused on the hepatic metabolism changes with the variation of lnc-HC expression. TG concentration in rat livers was significantly increased in the HCD group as compared with the control group while further increased with lnc-HC knockdown by intravenous (i.v.) injection of lnc-HC shRNA into the HCD rat model as compared with the NC shR-plus-HCD group ( Figure 6E) . Meanwhile, we also checked the important gene expression in model livers. As previously shown, hepatic lnc-HC expression was increased in the HCD group and significantly suppressed to normal level in the lnc-HC shR-plus-HCD group ( Figure 6F ). miR-130b-3p expression was completely synchronized with lnc-HC (Figure 6G ). In addition, PPARg expression was significantly increased in the HCD group, as compared with the NC group, and its increase was higher in the lnc-HC shR-plus-HCD group at both the mRNA and protein levels ( Figures 6H and 6I) . Meanwhile, the overlapping gene Slc25a15 of lnc-HC significantly decreased with HCD treatment in vivo ( Figure S5 ). These results also verified that lnc-HC positively regulates miR-130b-3p and that the lnc-HC/miR-130b-3p pathway negatively controls PPARg expression. Furthermore, lnc-HC/miR-130b-3p/PPARg delicately modulates hepatocytic lipid accumulation and might be a therapeutic target of NAFLD.
DISCUSSION
Aberrant lipogenesis and excessive accumulation of lipid droplets in liver indicate the pathogenesis of lipid metabolism disorders and NAFLD and is closely associated with diabetes, obesity, and atherosclerosis. However, the regulatory mechanism that controls hepatic lipogenesis remains uncertain. An approved therapeutic regime is lacking due to the complexity of NAFLD pathogenesis. Some existing studies have suggested that lncRNAs are emerging as an important modulator in almost all the biological processes, which includes hepatic lipid metabolism. [22] [23] [24] [25] [26] [27] In this study, we first identified PPARg as the most prominent target of lnc-HC in hepatocytic lipid metabolism. Further study elucidates that lnc-HC plays a repressive role in hepatic lipid accumulation.
By quantitative real-time PCR measurement of lipid MNR expression in lnc-HC overexpression and knockdown cells, PPARg was identified as the most prominent target of lnc-HC in hepatocytic lipid metabolism. Both in vivo and in vitro results elucidate that lnc-HC negatively regulates PPARg expression through miR-130b-3p. Mechanically, there have been three critical regulatory patterns for lncRNAs in regulating gene expression. First, lncRNA directly interacts with specific protein as an lncRNA-protein complex, and they cooperatively control target gene expression. 28, 29 Second, lncRNAs directly bind target mRNA and regulate mRNA stability. 30 Third, lncRNA and mRNA share the same recognition elements of miRNAs and increase the complexity of the miRNA regulation network, named the competitive endogenous pattern (ceRNA). 31, 32 We have reported that lnc-HC reduces the mRNA stability of Cyp7a1 and Abca1 through directly interacting with the co-regulator hnRNPA2B1. 21 Here, however, we have verified that lnc-HC regulates PPARg does not through lnc-HC-protein or lnc-HC-mRNA patterns after RNA pulldown and RIP assay. In turn, lnc-HC regulates PPARg expression through miR-130b-3p, which is different from the three classical regulation patterns described earlier. lnc-HC controlling miR-130b-3p expression is involved in the level of transcription as well as the processing of miRNA precursors. As we known, the upstream signal regulation of miRNA expression is complicated. Further studies need to be done to figure out the detailed regulation between lnc-HC and miR-130b-3p, which will help us understand not only the lncRNAs' function but also miRNAs processing.
www.moleculartherapy.org Our previous findings declared that lnc-HC negatively regulates hepatic cholesterol catabolism. In an 8-week high-fat HCD-induced hepatic lipid disorder model, serum concentrations of TG and HDL-C were significantly improved with lnc-HC suppression, which indicates a therapy potential of lnc-HC knockdown in body lipid metabolism disorder. Regarding model liver, lnc-HC suppression significantly increased TG concentration and vacuolar-like steatosis phenotype. These parameters point out the multifunction of lnc-HC in systemic lipid metabolism as a good effect in dyslipidemia but as side effects in hepatic lipid metabolism. In vitro, the knockdown of lnc-HC significantly upregulates FFA uptake genes Fatp-1 and aP2 and TG synthesis genes Acc2, Acsl1, and Dgat2, while it has little effect on hepatocytic very low-density lipoprotein (VLDL) formation genes Dgat1 and Mttp. In vivo, lnc-HC has little effect on serum LDL-C concentration, which is derived most partly from TG-enriched VLDL-C. These results could explain the hepatic TG increase and serum TG decrease. lnc-HC also negatively regulates mitochondrial FFA b-oxidation gene Cpt-1a, suggesting that its potential role in FFA consumption and utilization needs to be studied. Combined with the lipid accumulation test, we found that the comprehensive effect of lnc-HC is promoting FFA uptake, TG synthesis, and lipid droplet accumulation in cells. In vivo experiments showed that lnc-HC knockdown could aggregate lipid metabolism disorder in rat liver as vacuolar-like hepatic steatosis, which strongly indicates the protective role of lnc-HC in liver from excessive lipid droplet accumulation.
The exact signal that triggers lnc-HC expression is not measured in this study, but our previous work has reported that LXR agonist T0901317 could induce lnc-HC. 21 Thus, LXRs might provide an upstream signal that drives hepatic lipogenesis and lnc-HC overexpression. Here, lnc-HC represses hepatocytic lipid droplet accumulation through negative regulation of PPARg expression. It seems contradictory that FFA induces lnc-HC expression in CBRH-7919 and BRL3A cells, but lnc-HC overexpression suppresses hepatocytic lipid droplet formation, and knockdown lnc-HC expression increases hepatocytic lipid accumulation and liver TG concentration. Focused on this question, our quantitative real-time PCR results showed that PPARg was upregulated in FFA-treated cells and HCD-treated rat livers, while it increased much higher with the decrease of lnc-HC, and that miR-130b-3p expression was consistent with lnc-HC. Hence, it is suggested that PPARg could be upregulated much higher and lead to hepatocytic lipid overaccumulation without lnc-HC upregulation. This delicate modulation is consistent with the fine-tuning regulation pattern of lncRNAs and miRNAs. Here, our findings support a protection role of lnc-HC in preventing excessive lipogenesis, lipid accumulation, and NAFLD phenotype within the liver.
Taken together, we further identify the function and molecular mechanism of lnc-HC in inhibiting the accumulation of lipid droplets in liver through negatively regulating PPARg expression. Under FFA treatment, the upregulated lnc-HC protects hepatocytes from excessively overexpressing PPARg and helps avoid excessive formation of lipid droplets and lipid accumulation in liver. lnc-HC contributes hepatic lipid homeostasis through a versatile and complex mecha-nism, and these results may supply more detailed and integrated information to open new therapeutic strategies for the prevention and treatment of NAFLD.
MATERIALS AND METHODS
Animals
The animal experiments were approved by the Institutional Animal Ethics Committee of Xi'an Jiaotong University School of Medicine (permission ID: XJ2006Y039; Xi'an Jiaotong University, Xi'an, China), and were performed in accordance with the European Communities Council Directive 2010/63/EU for the protection of animals used for scientific purposes.
E3 rats originated from Lund University (Lund, Sweden) and were maintained in 12-h/12-h light/dark cycles under specific pathogenfree conditions. As previously described, 21 27 E3 rats (8-12 weeks old) were randomly divided into 4 groups, including a control group (n = 6), a high-fat HCD group (n = 7), an HCD and NC shRNA i.v. injection group (HCD, NCshR; n = 7), and an HCD and lnc-HC shRNA i.v. injection group (HCD, lnc-HCshR; n = 7). After being fed for 8 weeks with a normal diet or an HCD diet (10% fat, 4% cholesterol, and 2% sodium cholate), rats were euthanized by intraperitoneal (i.p.) injection of pentobarbital sodium (30 mg/kg) for blood collection, liver collection, and subsequent measurements.
Cell Culture CBRH-7919 cells were maintained in RPMI-1640 medium (Hyclone Laboratories, South Logan, UT, USA) containing 10% FBS (GIBCO, Gaithersburg, MD, USA). BRL3A cells were maintained in DMEM (GIBCO, Gaithersburg, MD, USA) containing 10% FBS (GIBCO, Gaithersburg, MD, USA). For lipid droplet formation and oil red O staining, CBRH-7919 cells and BRL3A cells were plated in a 12-well plate. After 24 h, cells were treated with mixed FFAs (1 mM; PA:OA, 1:2 in RPMI-1640 medium containing 2% FBS) for the indicated time. Then, oil red O staining was conducted to determine the cellular lipid droplet formation. Treated cells were visualized using microscopy (Olympus, Tokyo, Japan). TG and FFA levels of cells and rat livers were measured, respectively, by using the Total Triglyceride Assay Kit (Nanjing Jiancheng, Nanjing, China) or the Nonesterified Free Fatty Acids Assay Kit (Nanjing Jiancheng, Nanjing, China), following the manufacturer's instructions.
lnc-HC and Slc25a15 Gene Overexpression and Knockdown
Expression vector construction was as previously reported. 21 Briefly, lnc-HC DNA was obtained by PCR with PrimeSTAR GXL DNA Polymerase (Takara Bio, Beijing, China) and inserted into the pcDNA3.1(+) vector between Hind III and EcoR I sites, named pcDNA3.1-lnc-HC. The Slc25a15 coding region was obtained by PCR and inserted into the pcDNA3.1(+) vector between BamH I and Xho I, named pcDNA3.1-Slc25a15. Information on the primers is depicted in Table S1 . The shRNAs for lnc-HC or Slc25a15 gene knockdown were ordered and synthesized by GenePharma. 31 The target sequences for lnc-HC and Slc25a15 gene knockdown assay are depicted in Table S2 . After a 24-h transfection of these recombinant plasmids in CBRH-7919 cells by using Lipofectamine 2000 (Invitrogen, Waltham, MA, USA) according to the manufacturer's instructions, G418 was added into cell culture medium at 500 mg/mL to select the monoclonal stable cell lines respectively named overLnc-HC CBRH, overSlc25a15 CBRH, NCshR CBRH, and Lnc-HCshR CBRH. In lnc-HC interfered stable cells, small interfering RNAs (siRNAs) of PPARg were used to check the regulation of lnc-HC on the PPARg signaling pathway. The sequence information of PPARg siRNAs is depicted in Table S3 . miRNA primer information for quantitative real-time PCR is depicted in Table S4 .
Western Blotting
Protein was isolated from cells and rat model livers by using cell lysis buffer (Beyotime Biotechnology, Shanghai, China). Protein samples were separated by 10% SDS-PAGE gel and transferred onto polyvinylidene fluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA) according to the standard process. Gene expression at the protein level was detected by using rabbit anti-PPARg antibody (Abcam, Cambridge, MA, USA; 1:1,000), rabbit anti-Slc25a15 antibody (Abcam, Cambridge, MA, USA; 1:1,000) or rabbit anti-b-actin antibody (Santa Cruz Biotechnology, Shanghai, China; 1:500).
RNA Immunoprecipitation
For detecting the interaction between hnRNPA2B1 and candidate RNAs, RIP was performed as previously described. 21 . These vectors were used to determine the interaction between lnc-HC and candidate mRNAs by RIP assay. CBRH-7919 cells were co-transfected with pMS2-GFP (Addgene, Watertown, MA, USA) and pcDNA3.1-MS2-lnc-HC(sense) or pcDNA3.1-MS2-lnc-HC(antisense). After 48 h of transfection, cells were harvested to perform a RIP assay by using the Magna RIP RNA-Binding Protein Immunoprecipitation Kit (Millipore, Cleveland, OH, USA) according to the manufacturer's instructions. Rabbit anti-GFP antibody (Abcam, Cambridge, UK) or rabbit isotype IgG (Beyotime Biotechnology, Shanghai, China) per 5 mg were used in each respective RIP reaction system. 34 
RNA Pulldown
For detecting the interaction among lnc-HC, nucleus protein, and target mRNAs, RNA pulldown was performed by using the Pierce Magnetic RNA-Protein Pull-Down Kit (Pierce, Waltham, MA, USA). Briefly, biotin-labeled RNAs were transcribed in vitro by using Biotin RNA Labeling Mix (Roche, Basel, Switzerland) and T7 RNA polymerase (Ambion, Austin, TX, USA), and purified by phenolchloroform-isoamyl alcohol. After the binding between folded biotin-lnc-HC (sense or antisense) and nucleus protein, folded total RNA (250 mg) of CBRH-7919 cells was added into purified beads. After incubation and bead washing, the RNA component was isolated by phenol-chloroform-isoamyl alcohol for quantitative real-time PCR assay.
Dual-Luciferase Reporter Gene Assay
The recombinant vectors of PPARg 3 0 UTR (wild and mut) for checking interaction between miRNA candidates and PPARg by dual-luciferase reporter gene assay were constructed by GeneChem (Shanghai, China) and, respectively, named pPPARg-3 0 UTR-wild and pPPARg-3 0 UTR-mut. The DNA fragments of PPARg 3 0 UTR-wild and PPARg 3 0 UTR-mut are listed in Table S1 . CBRH-7919 cells were seeded into a 48-well plate. CBRH-7919 cells were co-transfected with pPPARg-3 0 UTR-wild (100 ng) or pPPARg-3 0 UTR-mut (100 ng) and miRNA small molecules (100 nM), such as mNCs, miR-130b3p mimics, iNCs, or miR-130b-3p inhibitors (purchased from GenePharma, Shanghai, China) by Lipofectamine 2000 reagent (Invitrogen, Waltham, MA, USA). After 24 h of transfection, the relative luciferase activity of each group was measured using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA), according to the manufacturer's instructions.
The promoter regions of miR-130b-3p and miR-130a-3p were generated by PCR. The primer information is depicted in Table S1 . They were cloned into pGL3-basic vectors between KpnI and Nhe I sites named pGL3-130b-3p-promoter and pGL3-130a-3p-promoter, respectively. For detecting the promoter activity of miR-130a-3p and miR-130b-3p, pGL3-promoter/pRL (90:10 ng per well) was cotransfected into CBRH-7919 or BRL3A cells (in a 48-well plate) for 24 h. pGL3-basic/pRL (90:10 ng per well) was used as NC. Luciferase activity was measured by using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI, USA), following the manufacturer's instructions.
Statistical Analysis
Quantitative data were expressed as means ± SEM. The statistical analysis of difference between groups was performed by unpaired Student's t test. A two-way ANOVA was used to analyze the differences of mRNA stability after a-amanitin treatment in indicated cell lines. p < 0.05 was considered statistically significant.
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